argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.
WebsiteLaarderhoogtweg 25
Amsterdam, 1101 EB
Netherlands
There are good reasons behind analyst's bullish views of this biotech stock.
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 14.22% on an annualized basis producing an average annual return of 26.19%. Currently, argenx has a market capitalization of $59.17 billion.
argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...
Investors talking about ARGX also mention
What share of all stock conversation is about ARGX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% +0 |
Of the messages about ARGX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 100% 0 | 100% +32.08 | 80.76% -12.07 | ||
| Bearish | — | 0% 0 | 0% -32.08 | 19.24% +12.07 |
Of the messages about ARGX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 22.73% | 15.76% | 56.19% | ||
| Technical Analysis | 0% | 77.27% | 29.09% | 7.85% | ||
| Analysts | 0% | 0% | 29.09% | 15.78% | ||
| Macro | 0% | 0% | 26.06% | 17.99% | ||
| Earnings | 0% | 0% | 0% | 2.1% | ||
| Controversies | 0% | 0% | 0% | 0.07% |
Of the messages about ARGX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 88.51% | 80.48% | 25.49% | ||
| Newcomers | 0% | 11.49% | 19.52% | 74.51% |